NCT06371157View on ClinicalTrials.gov

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

469

Participants

Timeline

Start Date

August 2, 2024

Primary Completion Date

October 25, 2025

Study Completion Date

May 23, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

AK104

intravenous

DRUG

Lenvatinib

oral

PROCEDURE

TACE

TACE (chemo and embolic agent injection into the hepatic artery)

OTHER

Placebo for AK104

intravenous

OTHER

Placebo for Lenvatinib

oral

Trial Locations (4)

210009

RECRUITING

Zhongda Hospital Southeast University, Nanjing

310005

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

410006

RECRUITING

Hunan Cancer Hospital, Changsha

450004

RECRUITING

Henan Cancer Hospital, Zhengzhou

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY